Revolutionizing Oncology: Vivos Inc.'s Journey Forward
Vivos Inc. (OTCQB: RDGL) is making significant strides in the medical device sector, focusing on FDA Investigational Device Exemption (IDE) approval to launch human clinical studies at leading healthcare institutions. The Company has effectively engaged with over 40 FDA reviewers, responding diligently to inquiries and successfully addressing concerns stemming from transitions within the review team.
Strategic Engagement with Regulatory Experts
To bolster its regulatory approach and navigate the complexities of the FDA's approval process, Vivos has partnered with John Smith, a distinguished regulatory expert with more than 25 years of experience in guiding complex medical device approvals. His extensive background includes working within the FDA's Office of Device Evaluation, allowing him to provide insights that resonate with the specific expectations of the review team at the FDA’s Center for Devices and Radiological Health (CDRH).
Focused Investigative Submissions
Under Mr. Smith's guidance, Vivos is preparing a second Pre-Submission focused on vital topics such as radiation dosimetry validation and the migration patterns of therapeutic agents. This submission will equip the FDA with detailed insights, facilitating formal feedback before the final IDE application. Such proactive measures are essential for aligning with established successful pathways for brachytherapy IDEs.
Expansion of Operations in India
In addition to its efforts within the FDA framework, Vivos is actively expanding its operations into international markets, specifically with the establishment of Vivos Scientific India LLP (VISL). This strategic move was officially authorized, with name reservation and incorporation processes currently underway. By situating VISL in Mumbai, Vivos aims to accelerate regulatory approval processes and establish a manufacturing center, fostering growth in both human and veterinary oncology.
Bridging Markets with Innovative Solutions
The formation of VISL also opens doors to access India's significant oncology market, valued at around $2 billion, along with a $100 million sector dedicated to veterinary therapies. As Vivos pursues Phase II clinical trials, they plan to initiate studies at several strategically chosen sites, further enhancing the breadth and depth of clinical data gathered while paving the way for regulatory submissions.
Building a Global Presence
Beyond its initiatives in India, Vivos is strategically positioning itself for expansion into various international markets, addressing unmet needs in the fields of oncology and veterinary care. The Company is leveraging the upcoming international manufacturing center to evaluate regulatory processes in regions known for their efficiency in device approvals. This comprehensive plan will enable Vivos to generate ample clinical evidence, strengthening its global brand recognition.
Growth Momentum in Animal Therapeutics
The IsoPet division has achieved remarkable growth, boasting an astonishing 800% year-over-year increase in therapies administered. This growth signifies the rising awareness and demand for IsoPet therapy among pet owners and veterinarians alike. Starting in the near term, Vivos aims to implement strategies focused on profitability while expanding its network of certified clinics.
Innovations in Manufacturing and Product Development
The Company acknowledges the risks associated with single-source manufacturing and is taking proactive steps to mitigate this. Plans are underway to cease fully outsourced manufacturing within the next year, transitioning to dedicated domestic and international production centers that will focus exclusively on Radiogel and IsoPet. These operational changes are anticipated to enhance product availability and control over production quality.
Intellectual Property Strategy
Maintaining a robust intellectual property portfolio, Vivos is continually expanding its patent holdings across numerous countries. Their innovations encompass hydrogel compositions, microparticles, and advanced applicators, which are vital for the future of their therapies. Collaborations, such as with Akina Inc., have enabled the company to enhance its product formulations based on extensive research, strengthening its competitive edge in the market.
Frequently Asked Questions
What is Vivos Inc. focusing on for regulatory approval?
Vivos Inc. is prioritizing securing FDA Investigational Device Exemption (IDE) to initiate clinical studies.
How is Vivos expanding its international presence?
The company has established Vivos Scientific India LLP to facilitate operations in India and is exploring other international markets.
What is the significance of IsoPet's growth?
IsoPet has demonstrated an 800% increase in therapy administration, indicating high demand and rapid adoption in veterinary medicine.
How is Vivos addressing manufacturing risks?
Vivos plans to shift from outsourced manufacturing to establishing dedicated production centers for better quality control.
What innovations is Vivos pursuing in its product lines?
Vivos is expanding its patent portfolio and collaborating with research institutions to enhance its therapeutic offerings and formulations.
